PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status

Allison M. Martin, W. Robert Bell, Ming Yuan, Lauren Harris, Bradley Poore, Antje Arnold, Elizabeth L. Engle, Laura Asnaghi, Michael Lim, Eric H. Raabe, Charles G. Eberhart

Research output: Contribution to journalArticle

Abstract

To evaluate a potential relationship between BRAF V600E mutation and PD-L1 expression, we examined the expression of PD-L1 in pediatric high- and low-grade glioma cell lines as well as a cohort of pediatric low-grade glioma patient samples. Half of the tumors in our patient cohort were V600-wildtype and half were V600E mutant. All tumors expressed PD-L1. In most tumors, PD-L1 expression was low (<5%), but in some cases over 50% of cells were positive. Extent of PD-L1 expression and immune cell infiltration was independent of BRAF V600E mutational status. All cell lines evaluated, including a BRAF V600E mutant xenograft, expressed PD-L1. Transient transfection of cell lines with a plasmid expressing mutant BRAF V600E had minimal effect on PD-L1 expression. These findings suggest that the PD-1 pathway is active in subsets of pediatric low-grade glioma as a mechanism of immune evasion independent of BRAF V600E mutational status. Low-grade gliomas that are unresectable and refractory to traditional therapy are associated with significant morbidity and continue to pose a treatment challenge. PD-1 pathway inhibitors may offer an alternative treatment approach. Clinical trials will be critical in determining whether PD-L1 expression indicates likely therapeutic benefit with immune checkpoint inhibitors.

Original languageEnglish (US)
Pages (from-to)74-85
Number of pages12
JournalJournal of neuropathology and experimental neurology
Volume79
Issue number1
DOIs
StatePublished - Jan 1 2020

Fingerprint

Glioma
Pediatrics
Cell Line
Immune Evasion
Neoplasms
Therapeutics
Heterografts
Transfection
Plasmids
Clinical Trials
Morbidity
Mutation

Keywords

  • BRAF
  • Immune response
  • Low-grade glioma
  • PD-1
  • PD-L1
  • Tumor infiltrating immune cells

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Neurology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status. / Martin, Allison M.; Bell, W. Robert; Yuan, Ming; Harris, Lauren; Poore, Bradley; Arnold, Antje; Engle, Elizabeth L.; Asnaghi, Laura; Lim, Michael; Raabe, Eric H.; Eberhart, Charles G.

In: Journal of neuropathology and experimental neurology, Vol. 79, No. 1, 01.01.2020, p. 74-85.

Research output: Contribution to journalArticle

Martin, AM, Bell, WR, Yuan, M, Harris, L, Poore, B, Arnold, A, Engle, EL, Asnaghi, L, Lim, M, Raabe, EH & Eberhart, CG 2020, 'PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status', Journal of neuropathology and experimental neurology, vol. 79, no. 1, pp. 74-85. https://doi.org/10.1093/jnen/nlz119
Martin, Allison M. ; Bell, W. Robert ; Yuan, Ming ; Harris, Lauren ; Poore, Bradley ; Arnold, Antje ; Engle, Elizabeth L. ; Asnaghi, Laura ; Lim, Michael ; Raabe, Eric H. ; Eberhart, Charles G. / PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status. In: Journal of neuropathology and experimental neurology. 2020 ; Vol. 79, No. 1. pp. 74-85.
@article{c642dc3688d74a779acfd16492eeb1f3,
title = "PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status",
abstract = "To evaluate a potential relationship between BRAF V600E mutation and PD-L1 expression, we examined the expression of PD-L1 in pediatric high- and low-grade glioma cell lines as well as a cohort of pediatric low-grade glioma patient samples. Half of the tumors in our patient cohort were V600-wildtype and half were V600E mutant. All tumors expressed PD-L1. In most tumors, PD-L1 expression was low (<5{\%}), but in some cases over 50{\%} of cells were positive. Extent of PD-L1 expression and immune cell infiltration was independent of BRAF V600E mutational status. All cell lines evaluated, including a BRAF V600E mutant xenograft, expressed PD-L1. Transient transfection of cell lines with a plasmid expressing mutant BRAF V600E had minimal effect on PD-L1 expression. These findings suggest that the PD-1 pathway is active in subsets of pediatric low-grade glioma as a mechanism of immune evasion independent of BRAF V600E mutational status. Low-grade gliomas that are unresectable and refractory to traditional therapy are associated with significant morbidity and continue to pose a treatment challenge. PD-1 pathway inhibitors may offer an alternative treatment approach. Clinical trials will be critical in determining whether PD-L1 expression indicates likely therapeutic benefit with immune checkpoint inhibitors.",
keywords = "BRAF, Immune response, Low-grade glioma, PD-1, PD-L1, Tumor infiltrating immune cells",
author = "Martin, {Allison M.} and Bell, {W. Robert} and Ming Yuan and Lauren Harris and Bradley Poore and Antje Arnold and Engle, {Elizabeth L.} and Laura Asnaghi and Michael Lim and Raabe, {Eric H.} and Eberhart, {Charles G.}",
year = "2020",
month = "1",
day = "1",
doi = "10.1093/jnen/nlz119",
language = "English (US)",
volume = "79",
pages = "74--85",
journal = "Journal of neuropathology and experimental neurology",
issn = "1554-6578",
number = "1",

}

TY - JOUR

T1 - PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status

AU - Martin, Allison M.

AU - Bell, W. Robert

AU - Yuan, Ming

AU - Harris, Lauren

AU - Poore, Bradley

AU - Arnold, Antje

AU - Engle, Elizabeth L.

AU - Asnaghi, Laura

AU - Lim, Michael

AU - Raabe, Eric H.

AU - Eberhart, Charles G.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - To evaluate a potential relationship between BRAF V600E mutation and PD-L1 expression, we examined the expression of PD-L1 in pediatric high- and low-grade glioma cell lines as well as a cohort of pediatric low-grade glioma patient samples. Half of the tumors in our patient cohort were V600-wildtype and half were V600E mutant. All tumors expressed PD-L1. In most tumors, PD-L1 expression was low (<5%), but in some cases over 50% of cells were positive. Extent of PD-L1 expression and immune cell infiltration was independent of BRAF V600E mutational status. All cell lines evaluated, including a BRAF V600E mutant xenograft, expressed PD-L1. Transient transfection of cell lines with a plasmid expressing mutant BRAF V600E had minimal effect on PD-L1 expression. These findings suggest that the PD-1 pathway is active in subsets of pediatric low-grade glioma as a mechanism of immune evasion independent of BRAF V600E mutational status. Low-grade gliomas that are unresectable and refractory to traditional therapy are associated with significant morbidity and continue to pose a treatment challenge. PD-1 pathway inhibitors may offer an alternative treatment approach. Clinical trials will be critical in determining whether PD-L1 expression indicates likely therapeutic benefit with immune checkpoint inhibitors.

AB - To evaluate a potential relationship between BRAF V600E mutation and PD-L1 expression, we examined the expression of PD-L1 in pediatric high- and low-grade glioma cell lines as well as a cohort of pediatric low-grade glioma patient samples. Half of the tumors in our patient cohort were V600-wildtype and half were V600E mutant. All tumors expressed PD-L1. In most tumors, PD-L1 expression was low (<5%), but in some cases over 50% of cells were positive. Extent of PD-L1 expression and immune cell infiltration was independent of BRAF V600E mutational status. All cell lines evaluated, including a BRAF V600E mutant xenograft, expressed PD-L1. Transient transfection of cell lines with a plasmid expressing mutant BRAF V600E had minimal effect on PD-L1 expression. These findings suggest that the PD-1 pathway is active in subsets of pediatric low-grade glioma as a mechanism of immune evasion independent of BRAF V600E mutational status. Low-grade gliomas that are unresectable and refractory to traditional therapy are associated with significant morbidity and continue to pose a treatment challenge. PD-1 pathway inhibitors may offer an alternative treatment approach. Clinical trials will be critical in determining whether PD-L1 expression indicates likely therapeutic benefit with immune checkpoint inhibitors.

KW - BRAF

KW - Immune response

KW - Low-grade glioma

KW - PD-1

KW - PD-L1

KW - Tumor infiltrating immune cells

UR - http://www.scopus.com/inward/record.url?scp=85076584612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076584612&partnerID=8YFLogxK

U2 - 10.1093/jnen/nlz119

DO - 10.1093/jnen/nlz119

M3 - Article

C2 - 31819973

AN - SCOPUS:85076584612

VL - 79

SP - 74

EP - 85

JO - Journal of neuropathology and experimental neurology

JF - Journal of neuropathology and experimental neurology

SN - 1554-6578

IS - 1

ER -